华府将向赛诺菲及葛兰素史克支付21亿美元以确保5,000万剂新型肺炎疫苗
外电报道,美国政府将向法国赛诺菲(Sanofi)及英国葛兰素史克(GlaxoSmithKline)支付21亿美元,以确保可取得5,000万剂新型肺炎疫苗,及支付相关测试及生产费用,每剂疫苗价格约42美元,与美国政府上周与美国药厂辉瑞及德国生物科技企业BioNTech签订的20亿美元协议下每剂疫苗40美元的价格相若。
另外赛诺菲及葛兰素史克并公布,正与欧盟27国就提供3亿剂疫苗行早期讨论。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.